- Trials with a EudraCT protocol (30)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
30 result(s) found for: Musculoskeletal Diseases AND Rheumatoid Arthritis AND Certolizumab Pegol.
Displaying page 1 of 2.
EudraCT Number: 2013-000337-13 | Sponsor Protocol Number: PreCePra | Start Date*: 2013-05-13 | |||||||||||
Sponsor Name:Universitätsklinikum Erlangen | |||||||||||||
Full Title: Prediction of response to Certolizumab Pegol treatment by functional MRI of the brain. A multi-center, randomized double-blind controlled study Prediction of response to Certolizumab-Pegol in RA (P... | |||||||||||||
Medical condition: Patients with active Rheumatoid Artrhitis (DAS28 > 3.2) despite DMARD therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003129-40 | Sponsor Protocol Number: FARM125FKN | Start Date*: 2017-01-05 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA | |||||||||||||
Full Title: PHASE 4, MULTICENTER RANDOMISED STUDY, AIMED AT EVALUATING THE MAINTENANCE OF REMISSION AFTER 6, 12, 18 AND 24 MONTHS FROM SUSPENSION OF TNF-ALPHA THERAPIES (ADALIMUMAB, ETANERCEPT, INFLIXIMAB, CER... | |||||||||||||
Medical condition: RHEUMATOID ARTHRITIS (RA) PATIENTS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003307-30 | Sponsor Protocol Number: RA0123 | Start Date*: 2015-04-16 | |||||||||||
Sponsor Name:UCB Celltech, UK Registered Branch of UCB Pharma SA | |||||||||||||
Full Title: A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Multiple Doses of UCB4940 Administered as Add-On to Certolizumab Pegol... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SK (Completed) CZ (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013758-33 | Sponsor Protocol Number: RA0028 | Start Date*: 2010-06-17 | |||||||||||
Sponsor Name:UCB Pharma S.A. | |||||||||||||
Full Title: MULTICENTER STUDY WITH A 16-WEEK DOUBLE-BLIND, PLACEBO-CONTROLLED (DURING THE INITIAL 2 WEEKS) RANDOMIZED PERIOD, FOLLOWED BY A 24-WEEK OPEN LABEL EXTENSION TO ASSESS MAGNETIC RESONANCE IMAGE-VERIF... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003536-23 | Sponsor Protocol Number: SFY13370 | Start Date*: 2013-02-20 | |||||||||||
Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
Full Title: A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intoleran... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BE (Completed) HU (Completed) ES (Completed) IT (Completed) SE (Completed) EE (Completed) NO (Completed) FI (Completed) NL (Completed) GB (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022243-38 | Sponsor Protocol Number: CNTO136ARA3003 | Start Date*: 2012-07-11 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) DE (Completed) GB (Completed) AT (Completed) ES (Completed) PT (Completed) BE (Completed) IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000385-35 | Sponsor Protocol Number: RA0069 | Start Date*: 2011-08-19 | |||||||||||
Sponsor Name:UCB PHARMA | |||||||||||||
Full Title: MULTICENTER, OPEN LABEL STUDY TO EVALUATE THE PREDICTABILITY OF EARLY RESPONSE TO CERTOLIZUMAB PEGOL (IN COMBINATION WITH METHOTREXATE) AS CONFIRMED AT WEEK 52 IN SUBJECTS WITH MODERATE-SEVERE RHEU... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005303-39 | Sponsor Protocol Number: M20-466 | Start Date*: 2021-08-31 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to ... | |||||||||||||
Medical condition: Moderate to Severe Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) SK (Completed) NL (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004300-65 | Sponsor Protocol Number: AGO/2016/012 | Start Date*: 2017-09-26 |
Sponsor Name:Ghent University Hospital | ||
Full Title: Optimizing the Biologic Treatment Strategy in Rheumatoid Arthritis (RA) Patients that have failed a Tumor Necrosis Factor-alpha (TNFα) blocking Agent by immunoscintigraphy with Technetium-labeled C... | ||
Medical condition: rheumatoid arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017998-37 | Sponsor Protocol Number: AGO/2009/015 | Start Date*: 2012-06-08 | |||||||||||||||||||||
Sponsor Name:Ghent University Hospital | |||||||||||||||||||||||
Full Title: Scintigraphic detection of tumor necrosis factor with radioactive labeled TNFα-blocker in patients with active rheumatoid arthritis and active axial and peripheric spondyloarthropathy. | |||||||||||||||||||||||
Medical condition: Patients with an active spondyloarthropathy and with an active rheumatoid arthritis; who were diagnosed according to the classic ACR-criteria (American College of Rheumatology) for rheumatoid arthr... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003812-30 | Sponsor Protocol Number: UP0017 | Start Date*: 2014-07-21 | ||||||||||||||||||||||||||
Sponsor Name:UCB Biosciences Inc. | ||||||||||||||||||||||||||||
Full Title: A MULTICENTER POSTMARKETING STUDY TO EVALUATE THE PLACENTAL TRANSFER OF CERTOLIZUMAB PEGOL IN PREGNANT WOMEN RECEIVING TREATMENT WITH CIMZIA® (CERTOLIZUMAB PEGOL) | ||||||||||||||||||||||||||||
Medical condition: Rheumatoid Arthritis Axial spondyloarthritis Psoriatic arthritis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001987-12 | Sponsor Protocol Number: IRFMN-RA-6453 | Start Date*: 2017-08-18 | |||||||||||||||||||||||||||||||
Sponsor Name:SOCIETA' ITALIANA DI REUMATOLOGIA - SIR | |||||||||||||||||||||||||||||||||
Full Title: Open-label, randomized controlled trial comparing tocilizumab to anti-TNF treatment and discovery of biomarkers for treatment selection in rheumatoid arthritis patients with inadequate response to ... | |||||||||||||||||||||||||||||||||
Medical condition: RHEUMATOID ARTHRITIS | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002852-26 | Sponsor Protocol Number: MS200588-0004 | Start Date*: 2016-12-07 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A multicenter, randomized, double-blind, Phase III trial to evaluate the safety, immunogenicity, and efficacy of MSB11022 compared with Humira® in patients with moderately to severely active rheuma... | |||||||||||||
Medical condition: moderately to severely active rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) HU (Completed) DE (Completed) LT (Prematurely Ended) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004419-22 | Sponsor Protocol Number: VX11-509-102 | Start Date*: 2012-05-23 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) HU (Completed) EE (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003255-54 | Sponsor Protocol Number: RGB-03-104 | Start Date*: 2015-01-21 | |||||||||||
Sponsor Name:Gedeon Richter Plc | |||||||||||||
Full Title: A Double-blind, Randomised, Comparative Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Evaluation of RGB-03 and MabThera® Combined with Methotrexate in Rheumatoid Arthritis Patients | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020839-39 | Sponsor Protocol Number: RA0056Amend4 | Start Date*: 2011-02-25 | |||||||||||
Sponsor Name:UCB Biosciences, Inc | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY WITH AN ACTIVE COMPARATOR TO EVALUATE THE EFFICACY AND SAFETY OF CDP6038 ADMINISTERED SUBCUTANEOUSLY FOR 12 WEEKS TO SUBJECTS WIT... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002374-36 | Sponsor Protocol Number: CO-STAR | Start Date*: 2014-11-19 | |||||||||||
Sponsor Name:The Karolinska Institutet, ClinTRID | |||||||||||||
Full Title: A multicenter, randomized, open-label, blinded-assessor, follow-up, phase 4 study in patients with rheumatoid arthritis who have completed the initial treatment part (active conventional therapy ve... | |||||||||||||
Medical condition: Rheumatoid arthritis (RA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000957-37 | Sponsor Protocol Number: AS0013 | Start Date*: 2017-09-25 | |||||||||||
Sponsor Name:UCB Biopharma SRL | |||||||||||||
Full Title: A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects with Active Ankylo... | |||||||||||||
Medical condition: Ankylosing Spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) GR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023880-17 | Sponsor Protocol Number: RR10/9589 | Start Date*: 2011-03-31 | |||||||||||
Sponsor Name:University of Leeds | |||||||||||||
Full Title: SWITCH: Randomised-controlled trial of switching to alternative tumour-necrosis factor (TNF)-blocking drugs or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initia... | |||||||||||||
Medical condition: Rheumatoid arthritis in patients who have failed to respond to an initial TNF-blocking drug | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021184-32 | Sponsor Protocol Number: GP13-201/GPN013A2301 | Start Date*: 2010-11-30 | |||||||||||
Sponsor Name:Hexal AG | |||||||||||||
Full Title: A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolera... | |||||||||||||
Medical condition: Refractory rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) ES (Completed) AT (Completed) IT (Completed) BE (Completed) EE (Completed) HU (Completed) PL (Completed) BG (Prematurely Ended) GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
